BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.
Additional eligibility requirements apply. Patients may enroll in support programs offered through Cell Therapy 360® after a certified CAR T cell therapy treatment center determines that Breyanzi is the right treatment for them.
If you have any additional questions about Breyanzi, please use the information provided below to contact a representative.
Call us at 1-800-321-1335.
This website is best viewed
using the horizontal display on
your tablet device.
This website is best viewed
using the vertical display on
your mobile device.